Status:
RECRUITING
Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome
Lead Sponsor:
October 6 University
Conditions:
Poly Cystic Ovary Syndrome
Eligibility:
FEMALE
18-50 years
Phase:
PHASE2
PHASE3
Brief Summary
Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet an...
Eligibility Criteria
Inclusion
- Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria.
Exclusion
- Patients with history of diabetes mellitus (Type 1 or 2).
- Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event within last three months
- Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4) inhibitors
- Eating disorders (anorexia, bulimia) or gastrointestinal disorders
Key Trial Info
Start Date :
November 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06142656
Start Date
November 25 2023
End Date
February 1 2026
Last Update
July 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
October 6 university hospital
Giza, Egypt, 12585